The International Red Cross and Red Crescent Museum
Av. de la Paix 17, Geneva, Switzerland
Wednesday 23 May 2018, 18h30 – 20h00
This meeting is by invitation only. Contact childfriendlymedicines [at] mmv.org to register for the event.
Children continue to be a highly vulnerable population in low and middle-income countries: 6 million children die every year before their fifth birthday from preventable diseases, including malaria, tuberculosis and neonatal sepsis. The healthy development of millions more children is cut short by chronic infection or permanent disabilities due to lack of diagnosis and lack of appropriate treatment.
Alongside the 71st World Health Assembly, Drugs for Neglected Diseases initiative (DNDi), the Global Fund to Fight AIDS, Tuberculosis and Malaria, Medicines for Malaria Venture (MMV) and Unitaid are hosting this meeting to invite an exchange on how best to leverage existing therapeutic options and adopt new ones, as well as improve access and use of life-saving treatments for children. The event also aims to help identify synergies with other child-friendly interventions.
Chair: Jabbin Mulwanda, Permanent Secretary, Ministry of Health, Zambia
- Opening remarks by the Chair
- Neglected populations: Developing child-friendly medicines
Bernard Pécoul, Executive Director, DNDi
- Pediatric treatments for malaria. Experiences from Africa and other regions
David Reddy, CEO, MMV
- Impact and challenges of Unitaid pediatric portfolio
Philippe Duneton, Deputy Executive Director, Unitaid
- The pre-qualification process and medicines for children
Emer Cook, Head of Regulation, Essential Medicines and Health Products Department, WHO
- Supporting countries to procure treatments better suited for children
Mariatou Tala Jallow, Senior Manager, Sourcing Department, Global Fund
- Concluding remarks by the Chair
Please note that full-scale interpretation from English cannot be provided due to logistical constraints. However, a French translation of the presentations will be made available at the meeting. Questions and comments in French during the discussion are welcome and will be interpreted.